Biovica signs master services agreement with US biotech subsidiary for cancer drug development testing services
Reuters2026/08/27 10:01- Biovica signed a master services agreement with a US biotechnology company to supply DiviTum TKa testing services for oncology drug development.
- Framework covers multiple programs targeting cell-cycle pathways where TKa measurements may be used; projects will be launched through separate work orders.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Gurman predicts iPhone Duo: The first foldable may set industry standards, Apple (AAPL.US) foldable could trigger a decade-long upgrade cycle
Renowned financial journalist Mark Gurman stated that Apple’s first foldable iPhone has the potential to elevate the still-experimental foldable phone category to an industry standard. He noted that this device, called the iPhone Duo, is one of Apple’s most influential products, ranking just behind the iMac, iPod, iPad, and Apple Watch.
Element Fleet drops bid for FleetPartners, exits sale process
Anchoring to Nasdaq! Anthropic races toward a record-breaking IPO with fundraising scale targeting SpaceX
Sources indicate that Anthropic PBC has chosen Nasdaq as its listing venue, and the potential IPO is expected to set a historic record.
10-Yr Benchmark Govt Yields - U.S. vs Other Nations
Crypto prices
More
